Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome

详细信息    查看全文

• 作者：Ibrahim Knani¹ ; Brian J. Earley² ; Shiran Udi¹ ; Alina Nemirovski¹ ; Rivka Hadar¹ ; Asaad Gammal¹ ; Resat Cinar² ; Harry J. Hirsch³ ; Yehuda Pollak³ ; Itai Gross³ ; Talia Eldar-Geva⁴ ; Daniela P. Reyes-Capo⁵ ; Joan C. Han⁵ ; ⁶ ; ⁷ ; Andrea M. Haqq⁸ ; Varda Gross-Tsur³ ; Rachel Wevrick⁹ ; Joseph Tam¹ ; ^{yossit@ekmd.huji.ac.il}
• 关键词：Endocannabinoids ; PWS ; Magel2 ; Peripheral CB1 blockade ; Metabolic syndrome
• 刊名：Molecular Metabolism
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：5
• 期：12
• 页码：1187-1199
• 全文大小：2990 K
• 卷排序：5

文摘

Circulating levels of endocannabinoids are increased in individuals with PWS. Magel2 is a negative regulator of hypothalamic endocannabinoid ‘tone’. Peripherally-restricted CB1 receptor blockade reverses obesity in Magel2-null mice.